浙江圣达生物药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告

Core Viewpoint - Zhejiang Sandar Biopharmaceutical Co., Ltd. has approved the use of idle raised funds for cash management, allowing for an investment of up to RMB 23 million in low-risk financial products to enhance fund efficiency and returns for shareholders [2][12]. Investment Overview - Investment Purpose: The aim is to improve the efficiency of raised funds and increase returns for the company and its shareholders while ensuring that the investment does not affect the construction and use of the raised funds [4]. - Investment Amount: The total amount for cash management is RMB 8 million [5]. - Source of Funds: The funds for cash management come from temporarily idle funds raised through a specific stock issuance [6]. - Basic Situation of Raised Funds: The company raised a total of RMB 267.61 million through the issuance of 17,840,666 shares at RMB 15 per share, with a net amount of RMB 261.42 million after deducting issuance costs [7]. Investment Products - Investment Method: The cash management products include structured deposits and large certificates of deposit, with a focus on high safety and liquidity [10]. - Investment Duration: The cash management is valid for 12 months from the date of board approval [11]. Review Procedures - The board and supervisory committee meetings held on July 7, 2025, approved the cash management proposal, which does not require shareholder meeting approval and is valid for 12 months [12]. Impact on the Company - The use of idle funds for cash management will not affect the company's normal operations or the ongoing investment projects, and it aims to enhance the efficiency of fund usage and increase returns for shareholders [15].